A new era of RNA biotherapeutics is here - but the platform has significant limitations with fragile, costly liquid drug products needing injection. Ziccum's unique LaminarPace technology can help unleash the full RNA potential. Thanks to a very gentle treatment based on a unique mass transfer principle, LaminarPace transforms delicate liquid biologics into robust, thermostable, dry powders while preserving the RNA activity and offering particle engineering possibilities. Discover LaminarPace, its solid, validated data for mRNA/LNP and the possibilities this disruptive but yet cost-efficient technology can bring to your next-generation biotherapeutics with Ziccum CEO Ann Gidner.